Xianjiang Wu

Xianjiang Wu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Journal of Global Health
Verified
Journal Article
Open access
SHSupei Hu
Supei Hu
XWXianjiang Wu
Xianjiang Wu
HJHua Jiang
Hua Jiang
Thyroid cancer has become a significant global health concern [1], with its continually increasing incidence over the past few decades making it one of the most common endocrine system malignancies [2,3]. This has had far-reaching consequences for the overall health and quality of life of patients [4,5]. The disease is characterised by disparities between various […]

17 March 2021 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Closed access
WZWei-Dong Zhang
Wei-Dong Zhang
LDLei Dai
Lei Dai
YWYing-Chun Wang
Ying-Chun Wang
YXYun-Yun Xie
Yun-Yun Xie
JGJian-Yao Guo
Jian-Yao Guo
XWXianjiang Wu
Xianjiang Wu
Background: Endoscopic thyroidectomy via areola approach (ETA) has been widely used in thyroidectomy for many years as it can effectively avoid a scar in the neck. Transoral endoscopic thyroidectomy vestibular approach (TOETVA) is newly applied and has gained popularity quickly. This study is to compare the safety and effectiveness of TOETVA and ETA. Materials and Methods: A total of 95 patients who underwent TOETVA or ETA with unilateral papillary thyroid carcinoma were enrolled in this study from March 2019 to February 2020. The basic information (such as gender, age), intraoperative hemorrhage, postoperative drainage volume, hospital durations, intraoperative and postoperative complications, operative time, central lymph node dissection time, total number of central lymph nodes, and number of metastatic central lymph nodes were compared. Results: The operative time of the TOETVA group was significantly longer than the ETA group (148.11±19.78 vs. 135.90±12.77 min, P<0.05). However, the result was opposite when central lymph node dissection time was compared (10.31±2.93 vs. 12.48±3.55, P<0.05). TOETVA had an advantage on total number of central lymph nodes over ETA (7.82±3.35 vs. 5.26±2.45, P<0.05). No differences were found between the 2 groups on other data. Conclusion: TOETVA and ETA have the similarity on surgical safety and effectiveness. TOETVA has its advantage on central lymph node dissection and might be a reasonable alternative for ETA and open surgery in the future.

7 June 2023 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Closed access
WZWei-Dong Zhang
Wei-Dong Zhang
LDLei Dai
Lei Dai
QLQi Le
Qi Le
KYKe-Jie Yu
Ke-Jie Yu
YWYing-Chun Wang
Ying-Chun Wang
XWXianjiang Wu
Xianjiang Wu
Background: Transoral endoscopic thyroidectomy vestibular approach (TOETVA) and gasless transaxillary endoscopic thyroidectomy (GTET) are 2 newly applied technologies. This study is to compare the 2 approaches from the aspects of effectiveness and safety. Materials and Methods: A total of 339 patients who underwent TOETVA or GTET with unilateral papillary thyroid carcinoma were enrolled in this study from March 2019 to February 2022. The 2 groups were compared in terms of patient characteristics, perioperative clinical results, and postoperative outcomes. Results: The operative time of the TOETVA group was significantly longer than the GTET group (141.39±16.11 vs. 98.45±12.24, P<0.05). The TOETVA group had advantages over GTET group when the reduction of parathyroid hormone was compared (19.18±17.43 vs. 23.07±15.72, P<0.05). Meanwhile, more parathyroids were detected in central neck specimens in GTET group (40/181 vs. 21/158, P<0.05). TOETVA had an advantage on total number of central lymph nodes over GTET (7.65±3.11 vs. 4.99±2.45, P0.05). No differences were found between the 2 groups on other data. Conclusions: TOETVA and GTET are both safe and effective for unilateral papillary thyroid carcinomas. TOETVA has advantage on protection of inferior parathyroid glands and harvest of central lymph node dissection. Meanwhile, GTET can save more time compared with TOETVA. Surgeons and patients should freely choose the approaches based on their demands.

11 June 2025 in Oncology Letters
Verified
Journal Article
Open access
PDF file
LXLisha Xu
Lisha Xu
WZWeidong Zhang
Weidong Zhang
YWYinchun Wang
Yinchun Wang
QLQi Le
Qi Le
YXYue Xie
Yue Xie
XWXianjiang Wu
Xianjiang Wu
Anaplastic thyroid cancer (ATC) is a highly malignant and aggressive endocrine tumor with the poorest prognosis among all thyroid cancer (TC) subtypes. Although ATC is extremely rare, treatment remains a notable challenge, as traditional therapies have exhibited very limited efficacy. Targeted small‑molecule inhibitors that disrupt molecular signaling pathways offer a potential therapeutic approach for patients with ATC. Lenvatinib, a tyrosine kinase inhibitor, has emerged as a promising therapeutic agent, which targets various factors involved in angiogenesis and tumor progression, including vascular endothelial growth factor receptor, platelet‑derived growth factor receptor α, fibroblast growth factor receptor and mast/stem cell growth factor receptor. Preclinical and clinical trials have demonstrated the efficacy of lenvatinib, both as monotherapy and in combination with other targeted therapy, chemotherapy, immunotherapy, warranting a comprehensive review of these studies. However, lenvatinib monotherapy was associated with a high incidence of adverse events (including hypertension, anorexia and proteinuria) and certain limitations, particularly drug resistance, emphasizing the need for optimized therapeutic strategies. In the present review, the efficacy and safety of lenvatinib monotherapy and combination therapies in the treatment of ATC were examined. Furthermore, the feasibility and limitations of different combination therapies were analyzed and compared. The present review aimed to provide insights into potential lenvatinib‑based regimens that could enhance survival outcomes and improve the quality of life for patients with ATC in the future.

2 February 2023 in Oncology Letters
Verified
Journal Article
Open access
PDF file
WZWeidong Zhang
Weidong Zhang
LDLei Dai
Lei Dai
KYKejie Yu
Kejie Yu
YWYingchun Wang
Yingchun Wang
QLQi Le
Qi Le
XWXianjiang Wu
Xianjiang Wu
The present study reports the case of a 64‑year‑old patient with papillary thyroid cancer (PTC) and tracheal invasion, along with primary lung cancer. Firstly, the patient received tumor electrocautery under tracheoscopy to enlarge the space for tracheal intubation. Next, the patient received one‑stage radical thyroidectomy, with window resection of the trachea and thoracoscopic radical resection of the lung cancer. The patient was discharged safely after several days of therapy. To the best of our knowledge, this case is the first reported case of a one‑stage radical thyroidectomy with a window resection of the trachea and thoracoscopic radical resection of the lung cancer in the literature. Simultaneous surgery for PTC with tracheal invasion and lung cancer is a great challenge for the patient and the surgeon. Appropriate surgical management of the tracheal invasion is of great importance to the operation and prognosis. This case may provide reference for surgeons in similar situations.

9 May 2024 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Closed access
WZWei-Dong Zhang
Wei-Dong Zhang
QLQi Le
Qi Le
KYKe-Jie Yu
Ke-Jie Yu
YWYing-Chun Wang
Ying-Chun Wang
XWXianjiang Wu
Xianjiang Wu
Background: Transoral endoscopic thyroidectomy vestibular approach (TOETVA) is newly applied technology. Carbon nanoparticles (CNs) are novel lymph node tracers that have been widely used in China to help remove central lymph nodes (CLNs) and protect the parathyroid glands (PGs) in open thyroid cancer surgery. This study is to evaluate the effectiveness and safety of CNs in TOETVA. Materials and Methods: A total of 158 patients who underwent TOETVA with unilateral papillary thyroid carcinoma were enrolled in this study from March 2019 to February 2022. The participants were divided into a CNs group (n=88) and a control group (n=70), based on whether they received a intraoperative injection of CNs or not. Meanwhile, the CNs group were additionally divided into 2 subgroups, leakage subgroup (n=26) and standard subgroup (n=62). The 2 groups and subgroups were compared in terms of patient characteristics, perioperative clinical results, and postoperative outcomes. Results: All common metrics had no significant differences were found between the CNs group and the control group (P>0.05). The standard subgroup of CNs group had advantage over the control group on PGs identification (59/62 vs. 59/70 for superior PG, 56/62 vs. 52/70 for inferior PG, P<0.05). Moreover, the standard subgroup harvested more CLNs than the control group (8.97±2.96 vs. 7.47±2.93, P<0.05). More operation time was spent on the leakage subgroup of CNs group than the control group (160.00±17.61 vs. 140.00±13.32, P<0.05). Meanwhile, the leakage subgroup had disadvantage on intraoperative hemorrhage (26.15±10.80 vs. 21.21±7.09, P<0.05) and hospital durations (4.96±0.72 vs. 4.57±0.69, P<0.05). Furthermore, the leakage group identified fewer inferior PG than the control group (7/26 vs. 52/70, P<0.05). Contrary to the standard subgroup, the CLNs of the leakage subgroup was also unsatisfactory compared with the control group (4.96±1.84 vs. 7.47±2.93, P<0.05). Conclusions: The application of CNs suspension tracing technology has a definite effect in TOETVA. It can improve the thoroughness of lymph node dissection in the central region and enhance recognition of the PG. However, refined extracapsular anatomy is indispensable to prevent CN leakage. Leaked CNs will also be counterproductive to the operation.